In a study of 1,057 patients, sotrovimab resulted in a 79% reduction in risk of hospitalization for more than 24 hours or death due to any cause, the companies said on Monday.
Similar therapies developed by rivals Regeneron and Eli Lilly have been approved by US regulators for treating non-hospitalized COVID-19 patients.